Perry 1989.

Methods	Six‐week randomised, double‐blind study
Participants	Outpatients fulfilling DSM‐III criteria for major depression (lasting more than 1 month), with a score of at least 20 on the Hamilton Rating Scale for Depression‐17 item (HDRS‐17). Age: over 18 years Exclusion criteria: pregnancy, lactation, absence of contraception, serious suicide risk, glaucoma, presence of cardiovascular arrythmias, hypertension, serious medical illness, including hepatic, renal, respiratory, hematologic disease, histiory of seizure, severe allergies or multiple drug reaction, psychotic patients and patients with DSM‐III diagnosis of organic mental disorder, substance abuse disorder within the past year, schizophrenia, paraniod disorder, bipolar disorder, use of MAOI in the past 14 days, lithium or any other psychotropic drug, use of trazodone or fluoxetine within 4 weeks of study entry.
Interventions	Fluoxetine: 21 participants Trazodone: 19 participants Fluoxetine dose range: 20‐60 mg/day Trazodone dose range: 50‐400 mg/day
Outcomes	HDRS‐17, Clinical Global Impression (CGI)
Notes	Funding: unclear
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further information
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Double blind, no further information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double blind, no further information
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Double blind, no further information
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Number and reasons for dropout were reported. Scores reported without denominator
Selective reporting (reporting bias)	Unclear risk	Only most frequent (at least 10%) adverse events reported Vital signs described
Other bias	Unclear risk	Funding: unclear